New HIV vaccine candidate shows promise in early trial
NCT ID NCT03284710
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tested an experimental HIV vaccine in 132 healthy adults to see if it is safe and triggers an immune response. Participants received different combinations of the vaccine with or without adjuvants (substances that boost immune response). The goal was to gather early data on safety and how the body reacts, which is a key step toward developing an effective HIV vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurum Tembisa CRS
Johannesburg, Gauteng, 1632, South Africa
-
Emavundleni CRS
Cape Town, Western Cape, 7750, South Africa
-
Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS
Maputo, Mozambique
-
Seke South CRS
Chitungwiza, Mashonaland East Province, Zimbabwe
-
Soweto HVTN CRS
Johannesburg, Gauteng, 1862, South Africa
-
eThekwini CRS
Durban, KwaZulu-Natal, 4013, South Africa
Conditions
Explore the condition pages connected to this study.